What Causes Schizophrenia? Genetics, Development, and Risk Factors
Author: Ukrainian Psychological Hub · Published: October 9, 2026 · Editorial Policy
Schizophrenia develops through the interaction of genetic liability, brain development, environmental exposures, and social and psychological circumstances over time. Researchers have identified many contributors to risk, but no single gene, childhood event, neurotransmitter change, infection, or exposure explains every case. Genetic susceptibility is substantial at the population level, while individual outcomes remain variable. The National Institute of Mental Health and the World Health Organization both describe schizophrenia as a condition with multiple interacting influences.
The word cause requires care. Some findings identify inherited contributions to vulnerability; some indicate associations that precede illness; some suggest biological mechanisms; others concern triggers that may bring forward psychosis in a susceptible person. Each category answers a different scientific question. A risk factor changes a probability within a studied population. It cannot establish why an individual developed schizophrenia, nor can it establish a diagnosis.
Schizophrenia is a clinical disorder that can involve delusions, hallucinations, disorganized thought or behavior, negative symptoms, cognitive difficulties, and changes in functioning. Psychosis is a syndrome that can occur in schizophrenia and in several other psychiatric, substance-related, neurological, and medical conditions. An isolated hallucination, family history, stressful experience, or genetic result does not diagnose schizophrenia. For the broader clinical overview, see Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery.
What Causes Schizophrenia? The Short Answer
The strongest explanation is multifactorial: thousands of common genetic variants and, for a minority of people, rare genetic changes contribute to vulnerability; developmental processes shape the brain across pregnancy, childhood, and adolescence; and particular environmental, biological, and psychosocial exposures are associated with later psychotic disorders. These influences may accumulate, interact, or operate differently across individuals. There is no validated single-cause account or general-purpose test that identifies which influence was decisive in a particular case.
Large genomic studies have implicated hundreds of associated regions, particularly processes involved in neuronal communication. A landmark Psychiatric Genomics Consortium genome-wide association study identified 287 genomic loci associated with schizophrenia. A complementary rare-variant sequencing study identified ultra-rare coding variants in 10 genes with substantial associations in the studied samples. These findings connect biological pathways to risk; they do not turn schizophrenia into a single-gene disorder.
Environmental evidence is heterogeneous. A 2026 umbrella review in World Psychiatry synthesized 69 reviews and meta-analyses, representing 970 individual studies and 221 candidate risk or protective factors for psychotic disorders. It graded findings by credibility and highlighted associations involving birth-related factors, social context, and frequent cannabis use. Because it examined psychotic disorders as a group, its estimates cannot be copied uncritically as schizophrenia-specific causal effects.
Causes, Risk Factors, Triggers, and Mechanisms: Four Different Questions
A cause, in the strict sense, contributes to producing an outcome. A risk factor is a characteristic or exposure statistically associated with greater probability of that outcome. A trigger is an event that may contribute to the timing or expression of symptoms in a vulnerable person. A mechanism is the biological, cognitive, developmental, or social process proposed to connect exposure and outcome.
These categories overlap in research but are not interchangeable. For example, cannabis use is associated with later psychotic outcomes, particularly with more frequent use, yet observational evidence must address confounding, reverse causation, dose, and vulnerability. A stressful period may precede first-episode psychosis without being an adequate explanation for the underlying disorder. Dopamine signaling can contribute to psychotic symptom expression without proving that schizophrenia begins with a universal dopamine deficiency or excess. The distinction is central to interpreting evidence responsibly.
Study design also matters. Family and twin studies estimate familial and genetic contributions. Genome-wide association studies identify genetic correlations. Prospective cohorts establish that an exposure preceded an outcome. Case-control studies compare histories and may be more affected by recall or selection differences. Mendelian randomization can strengthen certain causal inferences under its assumptions. Randomized trials can test the effects of interventions but rarely allocate people to potentially harmful developmental exposures. A 2018 umbrella review and 2025 transdiagnostic umbrella review show why the strength and specificity of observational associations need systematic evaluation.
How Much of Schizophrenia Risk Is Genetic?
Genetic influences make a major contribution to variation in schizophrenia liability across studied populations. Schizophrenia commonly shows familial aggregation, and twin studies consistently find greater diagnostic concordance in identical than in fraternal twins. In a nationwide Danish twin study, the estimated heritability was about 79%, while the reported concordance was 33% for identical twins and 7% for fraternal twins. The gap between high heritability and incomplete concordance is important: genetic liability is influential, and identical genetic makeup does not guarantee the same outcome. See Hilker and colleagues' Danish twin study.
Heritability of 79% means that under a particular statistical model, in a particular population and range of environments, genetic differences account for an estimated share of variation in an underlying liability to schizophrenia. It does not mean that 79% of any individual person's schizophrenia was caused by genes, that 79% of people carrying a given variant become ill, or that the remaining 21% can be assigned to a known set of life experiences. Heritability can vary across populations, time, diagnostic practices, and environmental conditions.
Family history is therefore informative but not deterministic. Risk is generally higher among close biological relatives of someone with schizophrenia than in the general population, but most relatives never develop the disorder, and many people diagnosed with schizophrenia have no known affected first-degree relative. Families share more than genes: some environments and healthcare-access patterns are also shared. The US National Library of Medicine's MedlinePlus Genetics explains why inheritance usually follows no simple Mendelian pattern.
Polygenic risk: Many common variants with small effects
Schizophrenia is highly polygenic. Most associated common DNA variants each shift statistical risk by a small amount, and their combined distribution differs across people. Genome-wide association studies compare large groups of diagnosed cases and controls to find such associations. Their discovery of hundreds of associated loci points toward neuron-specific biology, including excitatory and inhibitory signaling, rather than a single anatomical location or molecular switch. The 2022 Nature genomic mapping study provides one of the central demonstrations.
A polygenic risk score combines effects from many variants into a statistical index. Researchers use these scores to study inherited liability and relationships between traits. A score is not a diagnostic test for schizophrenia and cannot reliably tell one person whether or when illness will develop. Predictive performance also varies with the genetic ancestry represented in discovery samples, the outcome studied, and the absolute baseline risk. Translating genomic associations into equitable individual clinical prediction remains a substantial scientific problem.
Rare variants and copy-number changes
Some rare genetic changes have much larger effects than any single common variant. Studies have implicated ultra-rare damaging coding variants in particular genes and structural changes known as copy-number variants, which delete or duplicate stretches of DNA. Such variants may affect neural development, synaptic function, or broader neurodevelopmental syndromes. They explain a subset of cases and may have variable clinical presentations and incomplete penetrance.
The 2022 exome-sequencing meta-analysis implicated ultra-rare variants in 10 genes at a stringent significance threshold; observed effect sizes in that study varied considerably. A genetic variant with a high relative effect still does not imply that every carrier will develop schizophrenia. Moreover, research discovery of a risk variant is a different matter from clinically actionable genetic testing.
A 2026 systematic review and meta-analysis of clinical genetic testing examined 31 studies involving 20,476 people with schizophrenia and found clinically significant variants in approximately 6% overall, with substantial between-study heterogeneity and important geographic gaps. This is a detection estimate across particular testing settings and populations, not a recommendation to test everyone or an estimate of how much schizophrenia is genetic. Clinical genetic evaluation may be particularly relevant when there are developmental anomalies, intellectual disability, congenital features, or a suggestive family history. Decisions depend on specialist assessment, genetic counseling, consent, possible incidental findings, and whether a result would affect care.
Can schizophrenia skip a generation?
Family members may have different combinations of variants, environmental exposures, and protective circumstances. Some relatives may have no symptoms; others may experience different psychiatric or neurodevelopmental outcomes. This can look like the condition has skipped generations, but ordinary schizophrenia usually does not follow a predictable dominant or recessive inheritance sequence. A family tree alone cannot calculate a precise individual probability. MedlinePlus Genetics explains the complex inheritance pattern.
Brain Development and the Neurodevelopmental Model
The neurodevelopmental model proposes that developmental differences occurring before clinical onset may contribute to schizophrenia vulnerability. Relevant periods include fetal brain formation, birth and early childhood, maturation of neural networks during adolescence, and transitions into adulthood. This model helps explain why first clinical episodes often appear years after earlier biological or environmental influences.
Brain development depends on the formation, strengthening, organization, and modification of connections between neurons. Genes involved in synapses, neuronal maturation, and signaling can influence these processes. Environmental exposures can also affect development. However, no single developmental pathway has been established as necessary or sufficient in all cases. The National Institute of Mental Health notes that certain observed brain differences may begin before birth, while emphasizing that their significance varies.
Why schizophrenia often begins in adolescence or early adulthood
Adolescence and early adulthood involve marked developmental changes in cognition, social demands, sleep, stress responses, and brain network organization. Researchers investigate whether maturational processes make some vulnerabilities clinically apparent during these years. The temporal overlap is a research clue rather than proof that puberty itself causes schizophrenia. Childhood-onset schizophrenia remains rare, and later onset also occurs.
One influential hypothesis concerns synaptic pruning, the process by which neural connections are refined during development. A 2016 Nature study of complement component 4 connected common genetic variation associated with schizophrenia to complement-related biology and experimental models of synaptic elimination. It supports a plausible pathway in a complex disorder; it does not prove that everyone with schizophrenia has excessive synaptic pruning or that an imaging scan can measure and diagnose that mechanism.
The brain's timing is different from the timing of symptoms
A person may have inherited risk from conception, a prenatal exposure early in development, no apparent problems throughout childhood, and a psychotic episode many years later. The appearance of symptoms is one point in a longer developmental sequence. Researchers distinguish premorbid changes, nonspecific developmental differences, clinical high-risk states, first-episode psychosis, and confirmed schizophrenia. They are different clinical constructs with different predictive value. Early social withdrawal, concentration problems, anxiety, sleep disruption, or changes in school performance have many possible explanations and cannot establish a future schizophrenia diagnosis.
Pregnancy, Birth, and Early-Life Factors
Research links some prenatal and perinatal exposures with later schizophrenia-spectrum or psychotic disorders, including maternal infection, certain obstetric complications, and low birthweight. The evidence is largely observational and often reports modest relative associations. Pregnancy experiences are common, whereas schizophrenia remains comparatively uncommon; an individual exposure should not be presented as a prediction of future illness or a basis for parental blame.
A 2026 systematic review and meta-analysis of prenatal and childhood infections combined evidence from cohort studies and found associations between prenatal infection and later psychotic disorders (pooled relative risk 1.21, 95% CI 1.13–1.29) and between childhood infection and later psychosis (relative risk 1.31, 95% CI 1.07–1.60). These were psychosis-related outcomes across studies, not proof that a particular infection caused schizophrenia in an individual. Timing, type of infection, inflammatory responses, shared vulnerabilities, and confounding remain important questions.
Obstetric complications and birthweight
Low birthweight and certain complications around birth have repeatedly appeared in epidemiological research. The 2026 World Psychiatry umbrella review rated associations with birthweight below 2,000 grams and below 2,500 grams among its strongest epidemiological findings for psychotic disorders. Low birthweight may reflect a variety of pathways, including prematurity, placental factors, or other prenatal conditions. It is not itself a diagnosis or a single identified causal mechanism.
When studies combine obstetric complications into broad categories, they may group biologically different events. Retrospective accounts may differ from prospectively recorded data, and the disorder definition may vary from schizophrenia specifically to nonorganic psychosis generally. Clinical interpretation should therefore focus on the particular finding, not a generic statement that all birth complications cause schizophrenia.
Maternal health, nutrition, and immune hypotheses
Prenatal nutrition and inflammatory or immune processes are active areas of research. Folate-related findings have appeared in earlier umbrella reviews, but peripheral biomarker associations can be affected by nutrition, comorbidities, medication, and whether samples were obtained before or after diagnosis. A systematic umbrella review of schizophrenia-spectrum risk factors considered several promising associations while documenting heterogeneity and bias. A biomarker found after diagnosis cannot automatically be treated as a prenatal cause.
Maternal immune activation is a biologically plausible research framework connecting some infections and inflammatory responses to later developmental changes. Human epidemiological data and experimental models contribute different kinds of evidence; the exact causal pathway, exposure window, and applicability to individual cases remain uncertain. Standard prenatal healthcare, vaccination advice, infection treatment, and nutritional support should follow established obstetric guidance, not speculative schizophrenia-prevention regimens.
Childhood Adversity, Trauma, and Stress
Childhood abuse, neglect, severe adversity, and some other stressful experiences are associated with elevated risk of later psychotic outcomes in several bodies of research. These experiences may alter stress regulation, threat interpretation, social development, and access to safety and support, but they do not explain every case and do not always lead to psychosis. A person can develop schizophrenia without reported trauma, and most people exposed to adversity do not develop schizophrenia.
A 2017 umbrella review of schizophrenia-spectrum risk factors reported comparatively robust evidence for childhood adversities and stressful adult life events among studied nongenetic associations. A 2025 umbrella review comparing schizophrenia, bipolar disorder, and depression found childhood maltreatment was an important transdiagnostic association, meaning it was relevant across several diagnostic groups rather than specific to schizophrenia alone.
Stress may contribute through multiple routes: changes in sleep, physiological arousal, access to social support, substance use, perceived threat, and engagement with care. Some experiences described as triggers occur near the first episode but cannot reveal the full developmental history. Trauma-informed practice acknowledges the reality of adversity while evaluating symptoms and medical possibilities carefully and without assigning responsibility to the person or family.
Does family conflict or parenting cause schizophrenia?
No particular parenting style has been established as the sole cause of schizophrenia. Historical theories that blamed mothers or families were damaging and lack a valid basis as a general explanation. Familial communication and relationship stress can affect daily well-being, care engagement, or relapse vulnerability after illness begins; these are questions about environment and course, not evidence that a parent produced schizophrenia. Family psychoeducation and supportive communication may be clinically helpful precisely because families are important partners in care, not because they should be assigned blame. See NICE guidance on psychosis and schizophrenia.
Cannabis and Other Substance-Related Exposures
Cannabis is one of the most studied potentially modifiable environmental exposures associated with psychosis. Associations are generally stronger with more frequent use and higher-potency THC products, while age at exposure, underlying predisposition, measurement quality, and confounding matter. Cannabis-related psychotic symptoms, substance-induced psychotic disorder, and schizophrenia are distinct diagnostic possibilities that require clinical evaluation.
In the multicenter EU-GEI case-control study, daily cannabis use was associated with higher odds of psychotic disorder than never use, and the association was particularly marked for daily high-potency use. These are odds in the studied samples, not the probability that a user will develop schizophrenia. Authors' population-attributable calculations depended explicitly on a causal assumption and cannot be interpreted as established percentages of individual cases that would certainly have been prevented.
A 2024 umbrella review specifically mapping cannabis and psychosis outcomes found associations with earlier onset and development of psychosis and with relapse among people with psychotic disorders, while noting that reviews had not adequately resolved causality for every outcome. A broader BMJ umbrella review also found convergent signals of harm, particularly concerning adolescent psychosis risk. These findings justify clear risk communication, especially to adolescents and people already experiencing psychotic symptoms, without treating every user of cannabis as destined to develop schizophrenia.
Other stimulants, hallucinogens, prescribed medications, withdrawal states, and intoxicants can produce or contribute to psychotic presentations. Their role belongs in a differential assessment of the actual episode. A temporally associated substance does not automatically establish schizophrenia, nor does it rule out a co-occurring primary psychotic disorder. This causes article confines itself to schizophrenia risk; substance-use disorder treatment and general addiction care are separate clinical topics.
Urban Living, Migration, Social Exclusion, and Inequality
Large population studies have reported associations between psychotic disorders and urbanicity, migrant status, minority status in certain local contexts, and experiences shaped by social exclusion. Their interpretation requires attention to geography, discrimination, socioeconomic adversity, selection, neighborhood context, access to diagnosis, and the population from which the data were collected. A demographic category is not a biological cause.
The 2026 evidence-based atlas reported some strong statistical associations in particular British population groups as well as associations involving migration and minority status in areas of low ethnic density. Those results must be understood as location-specific epidemiology. They do not imply that a racial or ethnic identity biologically produces psychosis or that the same relative risks apply in every country. Discrimination, marginalization, exposure to adversity, diagnostic practices, and structural conditions are plausible contributors to investigate, with the details of causal pathways still under study.
Urban environments also differ in pollution, noise, crowding, housing instability, poverty, social fragmentation, and healthcare access. Measuring an association with residence does not identify which of these, if any, caused a particular outcome. A 2025 global mapping review of environmental risk factors documents geographic gaps in research and the difficulty of generalizing evidence from heavily studied populations.
Dopamine, Glutamate, Synapses, and Brain Networks
Neuroscience investigates how neural signaling contributes to schizophrenia vulnerability and psychotic symptoms. Dopamine is especially relevant to the expression and treatment of some positive symptoms, while glutamatergic signaling, inhibitory interneurons, synaptic organization, and wider network dynamics are also studied. A single neurotransmitter hypothesis cannot account for the full disorder, including differences in cognition, negative symptoms, developmental history, and functioning.
The effectiveness of dopamine receptor–acting antipsychotic medications is evidence about treatment of some symptoms. It is not a demonstration that one universal dopamine abnormality initiated every case. Similarly, rare-variant findings implicating genes involved in glutamate receptor biology provide mechanistic clues rather than proof that glutamate dysfunction has the same form in every patient. The 2022 rare-coding-variant analysis illustrates the breadth and convergence of implicated pathways.
Imaging studies also report group-level differences in brain structure, connectivity, and function. The distribution of findings overlaps substantially with variation among people without schizophrenia; medication, illness duration, substance exposure, general health, and statistical methods may influence results. Brain imaging is ordered when clinically indicated to investigate particular medical conditions, not as a stand-alone schizophrenia confirmation test. For general clinical evaluation, the NIMH schizophrenia resource describes the need for a full assessment.
Genes and Environment Interact Across Time
Gene–environment interaction means the association of an exposure with an outcome may differ according to genetic susceptibility, or the expression of inherited liability may depend on circumstances. Gene–environment correlation means inherited traits may influence which situations a person encounters, which can complicate interpretation of observational exposure studies. Both are research concepts with multiple designs and assumptions.
A developmental account therefore considers sequences rather than a checklist of independent causes. Early biological vulnerability may influence cognition or stress responsiveness; later experiences may shape coping, social support, sleep, substance exposure, and opportunities for treatment. Individuals can reach similar clinical presentations through different combinations of influences, while people with similar risk profiles may experience very different outcomes. Current evidence does not support assigning a percentage of responsibility to genes, parents, cannabis, stress, or one life event in an individual clinical history.
Which Risk Factors Have the Strongest Evidence?
Evidence strength depends on the exact outcome, study design, and assessment criteria. The 2026 Aymerich and colleagues umbrella review graded six reported associations as convincing for psychotic disorders and a further group as highly suggestive, including very frequent cannabis use. However, its categories measure epidemiological credibility, not proof of causation. Some factors were fixed birth characteristics or demographic patterns; others were potentially modifiable exposures. Different studies also differed in schizophrenia-specific versus broader psychotic-disorder outcomes.
An earlier Radua and colleagues umbrella review reported many associations with varying evidential strength and emphasized prospective evidence and contextual interpretation. The 2025 Miettunen and colleagues cross-diagnostic review found numerous associations across psychiatric outcomes but warned that many source meta-analyses were low quality or based on relatively few primary studies. The most responsible summary is that genetic contribution is strong, some environmental associations are replicated, and most detailed causal pathways remain under investigation.
Reading a risk estimate correctly
Relative risk compares the probability of an outcome among exposed and unexposed groups. An odds ratio compares odds rather than absolute probabilities; it cannot simply be read as a percentage chance of illness. Even a substantial relative association can correspond to a low absolute probability when the condition is uncommon. A population-attributable fraction estimates, under defined assumptions, the proportion of cases associated with a modifiable exposure in a particular population; it is especially sensitive to exposure prevalence and causal assumptions. These quantities do not substitute for an individualized clinical evaluation.
What Has Not Been Established as a Cause of Schizophrenia?
There is no evidence-based universal explanation based on a single parenting style, a single traumatic event, a particular personality trait, normal adolescent conflict, one stressful week, one infection, or one brain chemical measurement. Schizophrenia is also not caused by having multiple personalities; dissociative identity disorder and schizophrenia are separate diagnostic conditions. These popular narratives can delay assessment or add stigma.
No current routine genetic panel, consumer DNA report, blood biomarker, neurotransmitter measurement, or structural brain scan can independently diagnose schizophrenia or forecast its occurrence with clinical certainty in the general population. Some specialist tests identify clinically meaningful genetic or medical findings in selected contexts, which is a narrower and valuable role. The distinction between risk science and diagnostic practice matters for decisions about screening, referrals, and genetic counseling. MedlinePlus Genetics and the 2026 clinical-testing meta-analysis provide complementary perspectives.
Can Schizophrenia Be Prevented?
Schizophrenia does not currently have a universally validated prevention method. Research can identify risk-associated exposures and guide general health measures, but a favorable risk profile cannot guarantee prevention, and the presence of a risk factor does not guarantee illness. Practical public health measures include protecting prenatal health, responding to childhood adversity, reducing harmful substance exposures, and improving equitable access to mental healthcare. The evidence that these measures prevent schizophrenia specifically varies; their broader health value may be clearer than any measured schizophrenia-specific effect.
For someone already experiencing concerning changes, the clinical priority is timely assessment and appropriate support, rather than reconstructing a single cause. Early intervention for psychosis is based on improving access to assessment, reducing untreated symptom burden, and offering coordinated care. This does not mean every person with an early or attenuated symptom will transition to schizophrenia. See the NIMH guide to understanding psychosis and NICE adult psychosis guidance.
Reducing or avoiding frequent high-potency cannabis exposure is a reasonable risk-reduction discussion, particularly for adolescents, individuals with prior psychosis, and people with important clinical or family concerns. It should be presented without claims of guaranteed prevention. Clinical decisions involving medication, existing diagnoses, or changes in treatment require consultation with the treating clinician.
When a Possible Risk Factor Becomes a Clinical Question
A family history or an exposure may prompt understandable concern, but decisions about schizophrenia are based on symptoms, duration, functioning, longitudinal history, and differential diagnosis—not on a risk-factor count. Hearing a voice once, feeling suspicious during severe sleep loss, or finding a genetic association in a report has many possible interpretations. Persistent new hallucinations, fixed beliefs causing distress, marked confusion, disorganized behavior, or substantial changes in functioning warrant professional assessment.
Sudden-onset psychosis or confusion can arise from intoxication, medication effects, neurological disorders, infections, metabolic disturbances, delirium, or other acute medical conditions. Rapid deterioration, severe agitation, inability to maintain hydration or personal safety, catatonic signs, or suicidal thoughts require urgent evaluation according to local emergency resources. A person with imminent danger should receive emergency help now rather than wait for an online risk explanation. The NIMH Understanding Psychosis resource provides a clinically grounded overview of early assessment and care.
Treatment and recovery depend on individual circumstances and professional evaluation. Schizophrenia-specific care may include antipsychotic medication when indicated, psychosocial and family interventions, supported education or employment, attention to physical health, and shared decisions about goals and adverse effects. A cause or risk-factor article cannot replace the condition-specific treatment plan. For more on care and life after diagnosis, see Schizophrenia Treatment: Medication, Therapy, and Coordinated Care and Can You Recover From Schizophrenia? Outcomes and Long-Term Care.
Frequently Asked Questions
Is schizophrenia hereditary?
Schizophrenia has a substantial genetic component and occurs more often among biological relatives of affected people, but inheritance is complex. Most close relatives do not develop schizophrenia, and many diagnosed people have no known first-degree relative with the disorder. Familial history is useful information for a clinician; it is not a diagnostic result or an individual destiny. MedlinePlus Genetics provides the current NIH explanation.
What percentage of schizophrenia is genetic?
Twin studies have estimated population-level heritability around 60%–80%, with one Danish twin study reporting approximately 79%. This is a statistical estimate of variation in liability in a population under a model; it is not the percentage of one person's condition caused by DNA. Hilker et al. provide the design and interpretation of the estimate.
Can you develop schizophrenia without a family history?
Yes. A recognizable family history is absent in many people who receive a schizophrenia diagnosis. Polygenic risk may be present without an affected close relative, and non-genetic influences contribute to vulnerability and clinical expression. A family history cannot function as a necessary diagnostic criterion.
Does stress cause schizophrenia?
Severe adversity and stressful experiences are associated with psychotic outcomes in some populations and may influence onset or course. Stress is neither necessary nor sufficient as a universal explanation. Many exposed people never develop schizophrenia, and many people with schizophrenia have no clear identifiable stress trigger. Umbrella-review evidence evaluates the associations.
Can trauma cause schizophrenia?
Childhood trauma is associated with higher risk of several psychiatric outcomes, including psychosis, but individual causation is difficult to establish and the association is not specific to schizophrenia. A trauma-informed clinical assessment addresses both the person's experiences and the complete diagnostic differential. Miettunen et al. (2025) review transdiagnostic findings.
Does marijuana cause schizophrenia?
Cannabis use, especially frequent use and high-THC exposure, is associated with increased risk of psychotic outcomes, and causal contribution is supported by converging research but remains difficult to quantify for a specific person. Cannabis intoxication or substance-induced psychosis and schizophrenia require different diagnostic evaluation. The 2024 cannabis-psychosis umbrella review explains the limits of the evidence.
Can pregnancy complications cause schizophrenia later in life?
Certain pregnancy and birth factors are associated with increased population risk, but many affected pregnancies are followed by healthy development and the evidence does not establish that a particular complication caused schizophrenia. A 2026 umbrella review summarizes associations involving birthweight and other perinatal factors.
Is schizophrenia caused by too much dopamine?
Dopamine signaling plays a role in psychotic symptoms and is an important antipsychotic treatment target. Schizophrenia involves more extensive and diverse genetic, developmental, neural, and environmental influences. A dopamine-only explanation is incomplete and is not a testable diagnosis through a single routine dopamine measurement.
Can a genetic test tell whether I will get schizophrenia?
No general clinical genetic test can reliably predict future schizophrenia for an individual. In selected patients, specialist testing may uncover a clinically significant rare variant that is useful for broader medical and genetic evaluation. A 2026 meta-analysis estimated detection of clinically significant variants in about 6% of studied schizophrenia cases, with significant heterogeneity.
Does schizophrenia always become worse over time?
No. Clinical course, treatment response, daily functioning, and recovery trajectories vary. Risk factors do not prescribe an inevitable prognosis. Appropriate care, practical support, and shared decision-making matter after symptoms arise. See Can You Recover From Schizophrenia? Outcomes and Long-Term Care.
Related Articles
Schizophrenia: Symptoms, Causes, Diagnosis, Treatment, and Recovery — the central clinical overview of schizophrenia, psychotic symptoms, diagnosis, and the care pathway.
Schizophrenia Spectrum Disorders: Types, Differences, and Clinical Diagnosis — how schizophrenia fits among related clinical diagnoses.
Schizophrenia in Teenagers and Young Adults: Signs, Diagnosis, and Support — developmental and clinical questions during common ages of onset.
Schizophrenia Treatment: Medication, Therapy, and Coordinated Care — evidence-based treatment and integrated support.
Can You Recover From Schizophrenia? Outcomes and Long-Term Care — prognosis, functioning, and individualized recovery.
References
Aymerich, C., et al. (2026). Evidence-based atlas of risk and protective factors for psychotic disorders: An umbrella review to inform personalized prognosis and prevention. World Psychiatry, 25(3), 427–443. https://doi.org/10.1002/wps.70093
Brah, H. S., et al. (2026). Clinical genetic testing in schizophrenia: A systematic review and meta-analysis. Biological Psychiatry, 99(7), 541–549. https://doi.org/10.1016/j.biopsych.2025.09.010
Di Forti, M., et al. (2019). The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): A multicentre case-control study. The Lancet Psychiatry, 6(5), 427–436. https://doi.org/10.1016/S2215-0366(19)30048-3
Groening, J. M., et al. (2024). A systematic evidence map of the association between cannabis use and psychosis-related outcomes across the psychosis continuum: An umbrella review. Psychiatry Research, 331, 115626. https://doi.org/10.1016/j.psychres.2023.115626
Hilker, R., et al. (2018). Heritability of schizophrenia and schizophrenia spectrum based on the nationwide Danish twin register. Biological Psychiatry, 83(6), 492–498. https://pubmed.ncbi.nlm.nih.gov/28987712/
Khandakar, R., et al. (2026). Prenatal and childhood infections as risk factors for psychiatric disorders: A systematic review and meta-analysis. Neuroscience & Biobehavioral Reviews, 189, 106861. https://doi.org/10.1016/j.neubiorev.2026.106861
MedlinePlus Genetics. (2026). Schizophrenia. US National Library of Medicine. https://medlineplus.gov/genetics/condition/schizophrenia/
Miettunen, J., et al. (2025). Specificity of environmental risk factors for schizophrenia, bipolar disorders, and depressive disorders: Umbrella review. Psychological Medicine, 55, e368. https://doi.org/10.1017/S0033291725102584
National Institute of Mental Health. (n.d.). Schizophrenia. https://www.nimh.nih.gov/health/publications/schizophrenia
National Institute of Mental Health. (n.d.). Understanding psychosis. https://www.nimh.nih.gov/health/publications/understanding-psychosis
National Institute for Health and Care Excellence. (2014, updated). Psychosis and schizophrenia in adults: Prevention and management (CG178). https://www.nice.org.uk/guidance/cg178
Radua, J., et al. (2018). What causes psychosis? An umbrella review of risk and protective factors. World Psychiatry, 17(1), 49–66. https://doi.org/10.1002/wps.20490
Sekar, A., et al. (2016). Schizophrenia risk from complex variation of complement component 4. Nature, 530, 177–183. https://doi.org/10.1038/nature16549
Singh, T., et al. (2022). Rare coding variants in ten genes confer substantial risk for schizophrenia. Nature, 604, 509–516. https://doi.org/10.1038/s41586-022-04556-w
Tosato, S., et al. (2025). Environmental risk factors for schizophrenia spectrum disorders around the globe: A mapping review of the literature. Epidemiology and Psychiatric Sciences, 34, e47. https://doi.org/10.1017/S204579602510022X
Trubetskoy, V., et al. (2022). Mapping genomic loci implicates genes and synaptic biology in schizophrenia. Nature, 604, 502–508. https://doi.org/10.1038/s41586-022-04434-5
World Health Organization. (2026, September 11). Schizophrenia. https://www.who.int/en/news-room/fact-sheets/detail/schizophrenia